Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions

Read about the latest innovative technologies for combating infectious diseases

White paper: Harnessing innovative technologies for clinical trials involving emerging and re-emerging infectious diseases

The CDC and WHO declared antimicrobial resistance a worldwide problem contributing to high mortality rates and increasing healthcare costs. 

Antimicrobial resistance can then facilitate the emergence of new or previously recognized disease agents, and its damaging effects are increasingly being seen around the world.

This white paper highlights the challenges of emerging and re-emerging infectious diseases such as TB, MSSA/MRSA, and Ebola. 

At Q2 Solutions, we support of infectious disease clinical trials with a variety of tools including:
  • Niche and novel assay development 
  • DNA & RNA extraction and next-generation sequencing
  • Integrated local lab data management services
  • Global laboratory network held to rigorous quality standards and biosafety protocols

Learn how we are applying the latest technologies to provide insights for developing diagnostics and therapies with enhanced efficacy. These can then be used against target pathogens and their resistant variants for improved safety.




Authors:

Ayaskant PanyAyaskant Pany, MD
Director, Medical Laboratory, Central Laboratories South Africa, Q2 Solutions, a Quintiles Quest Joint Venture   

Dr. Pany is currently the Medical Laboratory Director, South Africa. His broad responsibilities include both administrative and technical management of the laboratory and its employees. He also oversees developmental activities for TB and microbiology at Q2 Solutions.


Sorika van NiekerkSorika van Niekerk, MSc, UP, SA
Senior Director/General Manager, Central Laboratories South Africa, Q² Solutions, a Quintiles Quest Joint Venture

Sorika van Niekerk is senior director of laboratory operations for Sub-Saharan Africa with a special interest and specific strategy to increase the infectious disease footprint for the laboratory.



Stephen MortlockStephen Mortlock, DSc.
Global Infectious Diseases and Microbiology Laison, Q2 Solutions, a Quintiles Quest Joint Venture 

Dr. Stephen Mortlock is the Global Infectious Diseases and Microbiology Liaison at a Q2 Solutions laboratory in the UK.  




Wayne HogrefeWayne R. Hogrefe, Ph.D., D (ABMLI)
Vice President, Vaccine unit, Q2 Solutions, a Quintiles Quest Joint Venture Company

Dr. Hogrefe is the vice president of the vaccine unit at Q2 Solutions, a Quintiles Quest Joint Venture, where he has had overall business development responsibilities for the past eight years